Lindilane

Paracetamol and Codeine Phosphate Hemihydrate, the active ingredient in Lindilane, is a Analgesic presented as a combination tablet for oral use. It provides pain relief and reduces fever in adults and children when prescribed.

GNH USA supplies Lindilane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lindilane, a combination analgesic, is used to manage pain and fever across several common conditions.

- Pain: provides relief of moderate to severe acute pain. - Fever: reduces elevated body temperature. - Headache: alleviates tension‑type or migraine‑associated headache.

Lindilane may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements. - Drowsiness: increased sleepiness. - Dizziness: sensation of light‑headedness. - Vomiting: occasional emesis. - Mild rash: transient skin irritation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, especially at high doses. - Severe allergic reaction: anaphylaxis with swelling, hives, or difficulty breathing. - Hepatic injury: potential liver damage with excessive paracetamol. - Dependence or addiction: risk of opioid‑related dependence. - Hypotension: low blood pressure episodes. - Seizures: rare convulsive events.

When prescribing Lindilane, consider the following safety measures. - Liver function assessment: evaluate hepatic status before initiating therapy. - Minimum effective dose: use the lowest dose that provides relief. - Respiratory caution: avoid in patients with compromised breathing. - Elderly monitoring: adjust use for older adults due to increased sensitivity. - CNS depressant avoidance: do not combine with other sedatives without supervision. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lindilane can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other opioids: additive respiratory depression. - MAO inhibitors: risk of severe serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation. - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): reduced conversion of codeine to morphine. - Hepatotoxic drugs (e.g., isoniazid, high‑dose paracetamol): increased liver injury risk.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): possible increased serotonergic effects. - Antihistamines: may augment drowsiness. - Antihypertensives: potential additive hypotensive effect. - Diuretics: monitor electrolyte balance. - Antacids: may affect absorption of paracetamol.